Andera Life Sciences, a Paris, France-based business unit of the asset management company Andera Partners specialising in innovative therapeutics and medical technologies , closed its BioDiscovery 6 fund, at €456m.
Existing institutional investors include funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.
The new fund will enable the management team to pursue its investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States. To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck.
The Andera Life Sciences partners include Sofia Ioannidou, Olivier Litzka, Gilles Nobécourt, Jan Van den Bossche, Raphaël Wisniewski.
Since its inception, the BioDiscovery fund family has raised over 1.1 billion euros and the team has invested in over eighty European and North American therapeutics and medical technology companies, thereby becoming a benchmark in investment dedicated to life sciences. The BioDiscovery funds have generated over forty remarkable exits, including around twenty companies sold, such as Corvidia, Arvelle, Sanifit and ReViral, and around twenty initial public offerings, such as Axonics, Nyxoah and LogicBio.
FinSMEs
10/10/2022